Studies have shown that 32-134D, a low-molecular-weight compound that inhibits HIF-1/2-mediated gene expression in HCC cells, when combined with anti-PD-1 therapy, increases HCC eradication rates in mice from 25% to 67% [135]. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.